Summary: Metabolism of nafamostat, a clinically used serine protease inhibitor, was investigated with human blood and liver enzyme sources. All the enzyme sources examined (whole blood, erythrocytes, plasma and liver microsomes) showed nafamostat hydrolytic activity. Vmax and Km values for the nafamostat hydrolysis in erythrocytes were 278 nmol W min W mL blood fraction and 628 mM; those in plasma were 160 nmol W min W mL blood fraction and 8890 mM, respectively. Human liver microsomes exhibited a V max value of 26.9 nmol W min W mg protein and a K m value of 1790 mM. Hydrolytic activity of the erythrocytes and plasma was inhibited by 5, 5?-dithiobis(2-nitrobenzoic acid), an arylesterase inhibitor, in a concentration-dependent manner. In contrast, little or no suppression of these activities was seen with phenylmethylsulfonyl ‰uoride (PMSF), diisopropyl ‰uorophosphate (DFP), bis(pnitrophenyl)phosphate (BNPP), BW284C51 and ethopropazine. The liver microsomal activity was markedly inhibited by PMSF, DFP and BNPP, indicating that carboxylesterase was involved in the nafamostat hydrolysis. Human carboxylesterase 2 expressed in COS-1 cells was capable of hydrolyzing nafamostat at 10 and 100 mM, whereas recombinant carboxylesterase 1 showed signiˆcant activity only at a higher substrate concentration (100 mM). The nafamostat hydrolysis in 18 human liver microsomes correlated with aspirin hydrolytic activity speciˆc for carboxylesterase 2 (r＝0.815, pº0.01) but not with imidapril hydrolysis catalyzed by carboxylesterase 1 (r＝0.156, p＝0.54). These results suggest that human arylesterases and carboxylesterase 2 may be predominantly responsible for the metabolism of nafamostat in the blood and liver, respectively.
Introduction
Nafamostat is a potent inhibitor of various serine proteases including trypsin, thrombin and C1 esterase. 1) This drug is widely used for the treatment of acute pancreatitis and disseminated intravascular coagulation. In addition, nafamostat is also prescribed as an anticoagulant in extracorporeal circulation. Nafamostat is an ester conjugate of 6-amidino-2-naphthol (AN) and p-guanidinobenzoic acid (pGBA), both of which themselves do not inhibit protease activities. 2, 3) Therefore, the pharmacological activity of nafamostat may be aŠected by the rate of hydrolysis. A pharmacokinetic study in rats was reported by Nanpo et al. 4) After nafamostat was administered intravenously to rats, this drug was hydrolyzed and eliminated from the blood at a half-life of approximately 2 min. The unchanged drug was transferred rapidly to various tissues including the liver, where approximately 5z of the administered drug was estimated to reach as an unchanged form at 2 min after the injection. The elimination of nafamostat from rat liver had a half-life of about 17 min and was faster than that from other tissues, such as the pancreas, lung and kidney, suggesting that the metabolism might contribute to nafamostat elimination from the liver. Major metabolites of nafamostat in rats were AN, its glucuronide conjugate and pGBA ( Fig. 1 ) and the unchanged form of nafamostat was less detectable in urine and feces of rats. Theseˆndings suggest that nafamostat may be hydrolyzed mainly by rat blood esterases and, to a minor extent, by liver esterases. In humans, a blood half-life of nafamostat elimination was approximately 23 min after continuous intravenous infusion 5) and longer than that of rats. 4) Such a species diŠerence in drug clearance from the blood has been reported previously 6) and could be explained by a higher esterase activity of rat blood. Accordingly, the contribution of human liver to the nafamostat hydrolysis would be larger than that of rat liver, suggesting that, in addition to the blood, human liver may be an important metabolic site of nafamostat. However, enzymes responsible for the hydrolysis of nafamostat in human blood and liver remain unclear.
In the present study, we investigated the in vitro metabolism of nafamostat using human blood and liver enzyme sources. We report herein that nafamostat is hydrolyzed by human erythrocytes, plasma and liver microsomes, although the hydrolytic activity of plasma is very low as compared with that of erythrocytes. Furthermore, our study suggests that arylesterases (EC 3.1.1.2) and carboxylesterase 2 (EC 3.1.1.1) are major enzymes responsible for nafamostat hydrolysis in human blood and liver, respectively. Preparation of enzyme sources: Blood samples were collected into tubes containing EDTA from healthy volunteers (4 males and 4 females aged 22-54 years, HB-1 to -8) from the scientiˆc staŠ. Informed consent was obtained from all subjects. A part of whole blood was stored at -809 C before analysis. Erythrocytes and plasma were prepared as reported previously. 7) Brie‰y, erythrocytes and plasma were separated by centrifugation at 880×g for 5 min. The plasma was removed and stored at -809 C before analysis. The erythrocytes were washed using an equal volume of saline. After centrifugation at 880×g for 10 min, the upper layer was removed and discarded. This procedure was repeated. The erythrocytes were then stored at -809 C before analysis. Thawing prior to assay lysed the whole blood and erythrocytes.
Materials and Methods

Materials
Human liver samples were obtained from a 57-yearold Japanese female (HL-1) and 16-year-old Japanese male (HL-2) who died in tra‹c accidents. The use of the human livers for these studies was approved by the Ethics Committee of Kanazawa University, Faculty of Medicine. Human liver microsomes were prepared as reported previously. 8) Sixteen human liver microsomes (HL-3 to -18) for the Reaction Phenotyping Kit Ver. 6 were purchased from XenoTech (Kansas, KS).
Expression of each human carboxylesterase isoform in COS-1 cells was carried out as described below. The pBluescript vector containing each open reading frame of human carboxylesterase 1 and 2 cDNAs 9) was digested with EcoR I. The cDNA fragment encoding carboxylesterase was ligated into a linearized mam-malian expression vector p91023(B), 10) which was kindly provided by Dr. R. J. Kaufman (Massachusetts Institute Technology) through Dr. K. Nagata (Tohoku University, Sendai, Japan). COS-1 cells were cultured in Dulbecco's modiˆed Eagle's medium supplemented with 10z heat-inactivated fetal calf serum, 50 IU W mL penicillin and 50 mg W mL streptomycin in a humidiˆed atmosphere containing 5z CO2 at 379 C. The cells (2× 10 6 ) were transfected with 2 mg of the expression plasmid carrying each human carboxylesterase isoform by Lipofectamine plus reagent according to the manufacturer's instructions. After 48 hr, the transfected cells were rinsed and harvested by trypsinization. The collected cells were suspended in phosphate-buŠered saline and sonicated to prepare cell lysates. The lysates were centrifuged at 9000×g for 20 min. The resultant supernatant (S9 fraction) was homogenized and kept at -809 C until use. The S9 fraction of COS-1 cells transfected with a plasmid carrying the carboxylesterase 2 cDNA ligated in the reverse orientation was used as a negative control.
Enzyme assays: The in vitro half-lives of nafamostat in human blood samples (HB-1 to -3) were determined as described below. Each blood fraction (450 mL of whole blood, erythrocytes and plasma) was preincubated at 379 C for 5 min. Reactions were initiated by addition of 50 mL of nafamostat solution (ˆnal concentration of 100 mM). Incubations were carried out at 379 C for 0, 5, 10, 20, 30 and 40 min, and terminated by the addition of 500 mL of acetonitrile containing methyl p-hydroxybenzoate (5 mg) as an internal standard (I.S.). After centrifugation, the supernatant was subjected to a high-performance liquid chromatography (Hitachi L-2130 pump, L-2200 autosampler and L-2400 UV detector, Hitachi, Tokyo, Japan) equipped with a Mightysil RP-18 GP column (4.6×250 mm, 5 mm, Kanto Chemical, Tokyo, Japan). The mobile phase was 100 mM sodium acetate buŠer (pH 3.0) containing 30 mM sodium 1-heptanesulfonate: acetonitrile (8:2). Elution was performed at a ‰ow rate of 0.5 mL W min. Nafamostat was monitored at a wavelength of 250 nm.
The hydrolytic activity for nafamostat was determined as described below. Nafamostat was incubated with each enzyme source (20 mL of whole blood, 13 mL of erythrocytes, 100 mL of plasma, 145 mg protein of liver microsomes and 50 mg protein of S9 fraction of COS-1 cells expressing each human carboxylesterase) and 100 mM Tris-HCl buŠer (pH 7.4) to make aˆnal volume of 500 mL. Incubations were carried out at 379 C for 15 min (whole blood), 10 min (erythrocytes), 20 min (plasma and liver microsomes) or 40 min (S9 of COS-1 cells expressing each human carboxylesterase). Other methods were the same as described for the in vitro halflives of nafamostat in human blood samples, except for the detection of AN formation.
To determine kinetic parameters for the nafamostat hydrolysis catalyzed by human blood fractions (HB-1) and liver microsomes (HL-1), nafamostat was incubated with either of these enzyme sources under the same conditions as mentioned above. In preliminary experiments, these reaction conditions were conˆrmed to ensure initial rates for the formation of AN. The nafamostat concentrations were 60-1250 mM for erythrocytes, 25-2000 mM for plasma and 10-1560 mM for liver microsomes. Data points wereˆtted to the Michaelis-Menten equation by nonlinear least-squares regression analysis with Origin 7.5J software (OriginLab, Northampton, MA). All kinetic parameters are given as mean±S.E.
The activity of imidapril hydrolysis was determined as described previously 11) with minor modiˆcations. Brie‰y, imidapril (100 mM) was incubated with human liver microsomes (200 mg protein) and 100 mM Tris-HCl buŠer (pH 7.4) in aˆnal volume of 500 mL at 379 C for 50 min, and the reaction was terminated by adding 450 mL of acetonitrile containing p-hydroxybenzoic acid (0.5 mg) as an I.S. After centrifugation, the supernatant was subjected to a high-performance liquid chromatography (Hitachi L-7100 pump and L-7400 UV detector, Hitachi) equipped with a Mightysil RP-18 GP column (4.6×250 mm, 5 mm, Kanto Chemical). The mobile phase was 82 mM sodium acetate buŠer (pH 3.0) containing 25 mM sodium 1-heptanesulfonate: acetonitrile (8.5:1.5). Elution was performed at a ‰ow rate of 1.0 mL W min. The imidaprilat formation was monitored at a wavelength of 237 nm.
The activity of aspirin hydrolysis was determined as described below. Aspirin (100 mM) was incubated with human liver microsomes (120 mg protein) and 100 mM Tris-HCl buŠer (pH 7.4) to make aˆnal volume of 500 mL. Incubations were carried out at 379 C for 40 min. Other methods were the same as described for the imidapril hydrolysis, except for the detection of salicylic acid formation.
Inhibition studies: Human erythrocytes, plasma and liver microsomes were preincubated with BW284C51 or ethopropazine at 379 C for 30 min. Human erythrocytes, plasma and the liver microsomes were preincubated with PMSF, DFP, BNPP or DTNB at 379 C for 5 min. Subsequently, the mixture was incubated with nafamostat (500 mM) in the same manner as described in the enzyme assays. All inhibitors except for DTNB in water were dissolved in dimethylsulfoxide and added to the incubation mixture at aˆnal dimethylsulfoxide concentration of 1z. IC50 values were calculated by nonlinear least-squares regression analysis with Origin 7.5J software (OriginLab).
Statistical analysis: The statistical signiˆcance of diŠerences between nafamostat hydrolytic activities of COS-1 cells expressing human carboxylesterases and the control cells was evaluated by means of the unpaired t-test. The correlation between hydrolytic activities of human liver microsomes was assessed by linear regression analysis. All statistical analyses were carried out with the program InStat (GraphPad Software, San Diego, CA).
Other method: Protein concentration was estimated by the method of Lowry et al., 12) using bovine serum albumin as a standard.
Results
In vitro half-lives of nafamostat in human blood samples: To determine the in vitro half-lives of nafamostat in human blood samples, nafamostat was incubated with human blood fractions (Fig. 2) . Nafamostat was decreased with a half-life of 18.8 min in whole blood. A similar half-life of the drug was seen in erythrocytes (18.1 min). In contrast, the half-life in plasma was 41.9 min and approximately twice longer than those in whole blood and erythrocytes.
Metabolism of nafamostat by human blood fractions and liver microsomes: Representative chromatograms are shown in Fig. 3 . Nafamostat was hydrolyzed by human whole blood, erythrocytes (Fig. 3B) , plasma and liver microsomes to produce AN. Hydrolytic activities of whole blood, erythrocytes and plasma at 100 mM nafamostat were 27.7±2.3, 68.5±6.7 and 6.48±0.40 nmol W min W mL blood fraction (mean±S.D., n＝8), respectively ( Table 1) . Since the hematocrit value in 8 subjects examined was 0.445±0.030, mean calculated activities of erythrocytes and plasma in whole blood were 30.5 and 3.60 nmol W min W mL whole blood, respectively. The sum of both calculated activities was roughly similar to the hydrolytic activity measured in the whole blood. On the other hand, the nafamostat hydrolytic activity was examined with human liver microsomes (HL-1 to -18). The liver microsomal activity at a substrate concentration of 10 mM was 0.0870±0.0368 nmol W min W mg protein (n＝18), ranging from 0.0521 to 0.187 nmol W min W mg protein.
Kinetic analysis for the nafamostat hydrolysis was carried out with human blood fractions (HB-1) and the liver microsomes (HL-1) ( Table 2) All determinations were performed in duplicate. Thus, the Vmax W Km value was 18.0 mL W min W mL blood fraction and only 1 W 25 of that for the erythrocytes. With respect to human liver microsomes, the V max and Km values were 26.9 nmol W min W mg protein and 1790 mM, respectively. The nafamostat hydrolytic activities at higher substrate concentrations were not determined with the plasma and liver microsomes because of the low solubility of nafamostat in reaction mixtures containing these enzyme sources. EŠects of inhibitors on nafamostat hydrolysis in human blood fractions and liver microsomes: To clarify human blood and liver esterases responsible for the nafamostat hydrolysis, the eŠects of various esterase inhibitors on the nafamostat hydrolytic activity were examined with human blood fractions (HB-1) and the liver microsomes (HL-1) ( Table 3 ). The hydrolytic activity for nafamostat in human erythrocytes was inhibited by DTNB (arylesterase inhibitor) 13) in a concentration-dependent manner: the hydrolysis was completely suppressed by 1000 mM DTNB. The plasma activity was also decreased by the addition of DTNB. In contrast, little or no inhibition of hydrolytic activities in the erythrocytes and plasma was seen with PMSF (serine esterase inhibitor), DFP (inhibitor for cholinesterase and carboxylesterase), BNPP (carboxylesterase inhibitor), 14) BW284C51 (acetylcholinesterase inhibitor) and ethopropazine (butyrylcholinesterase inhibitor). The hydrolytic activity of human liver microsomes was potently inhibited by PMSF, DFP and BNPP. IC50 values for PMSF (0.25-25 mM), DFP (0.005-0.5 mM) and BNPP (0.05-5 mM) were 9.64, 0.266 and 0.262 mM, respectively. In contrast, the liver microsomal activity was less decreased by the addition of BW284C51, ethopropazine and DTNB.
Metabolism of nafamostat by recombinant human carboxylesterases: Metabolism of nafamostat was investigated with S9 fractions from COS-1 cells expressing human carboxylesterases 1 and 2 (Fig. 4) . The hydrolytic activities at 10 and 100 mM nafamostat in the cells expressing carboxylesterase 1 were 0.0671±0.0138 and 0.473±0.080 nmol W min W mg protein (mean±S.D., n＝3), respectively. On the other hand, the corresponding activities of the cells expressing carboxylesterase 2 were 0.0864±0.0163 and 0.753±0.163 nmol W min W mg protein, respectively. The S9 fraction of control cells without human carboxylesterases showed nafamostat hydrolytic activities with 0.0437±0.0158 and 0.286±0.083 nmol W min W mg protein at 10 and 100 mM nafamostat, respectively. The nafamostat hydrolytic activity of the cells expressing human carboxylesterase 1 was signiˆcantly higher than that of the control cells only at a substrate concentration of 100 mM (pº0.05). The S9 fraction of the cells expressing carboxylesterase 2 showed signiˆcantly greater activities at 10 and 100 mM nafamostat in comparison to that of the control cells (pº0.05).
Correlation between hydrolyses of nafamostat and carboxylesterase isoform-speciˆc substrates in human liver microsomes: To clarify the involvement of carboxylesterases 1 and 2 in the nafamostat hydrolysis in human liver microsomes, correlation analysis between nafamostat hydrolytic activities and carboxylesterase isoform-speciˆc activities was carried out with 18 human liver microsomes (HL-1 to -18) (Fig. 5) . The nafamostat hydrolysis correlated highly with the hydrolytic activity for aspirin, which was a substrate of carboxylesterase 2 15) (r＝0.815, pº0.01). In contrast, there was no signiˆcant correlation between the nafamostat hydrolysis and the imidapril hydrolysis catalyzed by carboxylesterase 1 15) (r＝0.156, p＝0.54).
Discussion
A previous clinical study has demonstrated that nafamostat is hydrolyzed to produce AN and pGBA in humans. 5) Since these metabolites have no ability to inhibit protease activities, 2, 3) the hydrolysis of nafamostat is an important determinant in‰uencing its pharmacological eŠects. However, the metabolism of nafamostat is not fully understood.
Atˆrst, we focused on the involvement of blood esterases in the nafamostat hydrolysis because nafamostat was hydrolyzed rapidly after intravenous administration to humans 5) and rats. 4) In the present study, nafamostat was metabolized by whole blood, erythrocytes and plasma. The in vitro half-life of nafamostat disappearance in human whole blood and erythrocytes, in contrast to the plasma, was similar to the in vivo half-life in blood reported previously. 5) Interestingly, kinetic analysis suggests that the hydrolytic activity for nafamostat is predominantly localized in the erythrocytes. A few examples of drugs that are mainly hydrolyzed by the erythrocytes in human blood have been previously reported. 6, [16] [17] [18] Inhibitory eŠect of DTNB on the nafamostat hydrolysis in human erythrocytes suggests the involvement of arylesterase. This enzyme has been shown to be present in the cytosol of erythrocytes 19) and hydrolyzes a small number of drugs such as aspirin 13) and TEI-9090 (isocarbacyclin methyl ester). 6) Other esterases localized in the erythrocytes include acetylcholinesterase (EC 3.1.1.7) 20) and carboxylesterase. 21) These esterases appear not to be involved in the nafamostat hydrolysis because PMSF, DFP, BW284C51 and BNPP showed no signiˆcant inhibition. When acetylthiocholine (1000 mM) was used as a substrate, the hydrolytic activity of the erythrocytes used in this study was similar to that obtained by Reiner et al. 22) and was completely inhibited by 10 mM BW284C51 (data not shown). Thus, the blood sample used contains a functional acetylcholinesterase.
Inhibitory eŠects of various esterase inhibitors on the plasma activity for nafamostat suggest that plasma arylesterase may be responsible for nafamostat hydrolysis ( Table 3) . A well-characterized plasma arylesterase is paraoxonase. 23) However, the plasma esterase hydrolyzing nafamostat found in this study is not paraoxonase because paraoxonase requires calcium for catalytic activity. Smith and Cole 24) previously identiˆed a plasma arylesterase as the enzyme hydrolyzing heroin. This enzyme exhibits a hydrolytic activity for heroin without calcium, in contrast to paraoxonase. Thisˆnding and our result suggest that calciumindependent arylesterase(s) may be present in human plasma. Another well-known plasma esterase is butyrylcholinesterase (EC 3.1.1.8), which plays an important role in drug metabolism in the blood. 25) In this study, 10 mM ethopropazine failed to inhibit nafamostat hydrolysis catalyzed by human plasma ( Table 3) . In contrast, this inhibitor at a concentration of 10 mM showed a complete suppression of hydrolytic activity for butyrylthiocholine (1000 mM) in the same enzyme source (data not shown). These results exclude the possibility that butyrylcholinesterase contributes to the nafamostat hydrolysis in human plasma.
Next, we investigated the involvement of liver esterases in nafamostat hydrolysis because the elimination of nafamostat from the liver was faster than those from other tissues in rat.
4) The present study demonstrated that human liver microsomes were capable of hydrolyzing nafamostat. The hydrolytic activities of 18 human liver microsomes varied by 3.6-fold. A previous study determined that microsomal carboxylesterase activities in 12 human livers exhibited large interindividual variations, ranging from 4.8-(acetanilide) to 44.7-(p-nitrophenyl propionate) fold.
26) The variability in nafamostat hydrolytic activities of human liver microsomes was smaller than those in the carboxylesterase activities reported by Hosokawa et al. 26) Inhibition study using PMSF, DFP and BNPP suggests that carboxylesterase is responsible for the nafamostat hydrolysis in human liver microsomes ( 35) proposed that these isoforms were classiˆed into four families. Among them, carboxylesterases 1, 2 and 4 are expressed in the liver. 34, 36) However, carboxylesterase 4 is most likely not involved in the nafamostat hydrolysis in human liver microsomes, since it has been previously reported that this isoform is less sensitive to inhibition by PMSF. 33, 34) The enzyme assay using recombinant human carboxylesterases indicated that carboxylesterase 2 alone was capable of hydrolyzing nafamostat at a lower substrate concentration (10 mM) (Fig. 4) . Furthermore, correlation analysis with human liver microsomes showed that the nafamostat hydrolytic activity at a substrate concentration of 10 mM correlated only with hydrolytic activity of aspirin, a speciˆc substrate for carboxylesterase 2 (Fig. 5) . These results suggest that carboxylesterase 2 is mainly responsible for the nafamostat hydrolysis in human liver microsomes. However, we cannot exclude the possibility that carboxylesterase 1 might be involved in the nafamostat hydrolysis catalyzed by human liver microsomes because the recombinant carboxylesterase 1 revealed signiˆcant activity at a higher substrate concentration (100 mM) (Fig. 4) . Both relative activities and expression levels of carboxylesterases 1 and 2 would determine the contribution of these isoforms to the nafamostat hydrolysis in human liver microsomes.
A recent report has proposed that carboxylesterase 2 recognizes a bulky alcohol group and a relatively smaller acyl moiety, which are held as acyl-enzyme intermediates and released as the alcohol product, respectively. 37) Irinotecan is an ester prodrug of 7-ethyl-10-hydroxycamptothecin (SN-38) and 4-piperidino-piperidine-carboxylic acid, and is e‹ciently hydrolyzed by this isoform. 15) For aspirin, hydrolysis of the acetyl ester bond is catalyzed by carboxylesterase 2 to form salicylic acid and acetic acid. 15) Furthermore, it has been reported that the p-guanidinobenzoyl ester linkage of camostat is hydrolyzed exclusively by this isoform. 15) These characteristics of carboxylesterase 2 appear to be true for nafamostat hydrolysis.
In this study, we failed to demonstrate the involvement of erythrocyte carboxylesterase in nafamostat hydrolysis, in contrast to that of the liver microsomal carboxylesterases. It may be assumed that erythrocyte carboxylesterase has diŠerent substrate speciˆcity from carboxylesterases expressed in human liver microsomes.
The question of to what extent human blood and liver esterases contribute to the nafamostat hydrolysis in vivo is raised from our results. To our knowledge, however, detailed pharmacokinetic data of nafamostat in humans, containing plasma protein binding and transport across erythrocyte membrane, have not been reported so far. 5) Although it should be noted that nafamostat is exposed to the blood at theˆrst step, further studies are needed to quantify the compartment where this drug is metabolized.
The present study conclusively determined that nafamostat was hydrolyzed by human blood fractions and liver microsomes. Our results suggest that arylesterases and carboxylesterase 2 may be mainly responsible for nafamostat hydrolysis in human blood and liver, respectively.
